儿童肺纤维化治疗 - 我们从成年人的研究中学到了什么?
Michael B Jia1, Dominic A Fitzgerald2
1Department of Respiratory Medicine, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Paediatric respiratory reviews
|December 27, 2023
概括
儿童肺纤维化 (PF) 管理落后于成人护理,对新型抗纤维化药物如nintedanib的证据有限. 为了为患有这种罕见疾病的儿童建立安全有效的治疗方法,需要进行更多的研究.
科学领域:
- 儿科肺病学 儿科肺病学
- 罕见疾病 罕见疾病
- 间歇性肺部疾病 间歇性肺部疾病
背景情况:
- 儿科肺纤维化 (PF) 是儿童间歇性肺病 (CHILD) 的罕见并发症.
- 目前关于PF管理的儿科指南是有限的,并没有跟上成人的进步.
- 抗纤维菌药物 (nintedanib,pirfenidone) 是成年人的标准药物,但在儿童中基本上没有研究过.
研究的目的:
- 突出在PF管理中更新儿科指南的关键需求.
- 为了强调儿童群体对抗纤维菌疗法的缺乏研究.
- 倡导进一步研究目前的治疗方法和儿科PF的新疗法.
主要方法:
- 关于成人和儿科PF管理的现有文献的审查.
- 对儿童抗纤维菌药物的现有证据缺口的分析.
- 确定需要进一步临床试验和研究的领域.
主要成果:
- 成人和儿科PF治疗策略之间存在显著的差异.
- 尼丁达尼布和皮尔芬尼等抗纤维菌药物尚未在儿科患者中得到充分测试.
- 最近对宁泰达尼布和氧化的试验有希望,但强调需要进行更广泛的研究.
结论:
- 迫切需要专门的儿科研究来指导PF管理.
- 评估儿童新兴抗纤维菌治疗的安全性和有效性至关重要.
- 弥合儿科PF的知识差距对于改善患者的治疗结果至关重要.
更多相关视频
02:46A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
Published on: January 20, 2023
3.6K
07:38A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
Published on: April 13, 2018
11.5K
相关概念视频
COPD: Pathogenesis and Clinical Features
279
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
279
Cystic Fibrosis: Management
166
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
166
Pulmonary Function Tests
334
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
334
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
183
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
183
